|1.||Morris, Thomas: 9 articles (05/2013 - 05/2009)|
|2.||Spinella, Francesca: 7 articles (10/2012 - 06/2006)|
|3.||Di Castro, Valeriana: 7 articles (10/2012 - 06/2006)|
|4.||Rosanò, Laura: 7 articles (10/2012 - 06/2006)|
|5.||Bagnato, Anna: 7 articles (10/2012 - 06/2006)|
|6.||Natali, Pier Giorgio: 6 articles (04/2011 - 06/2006)|
|7.||Miller, Kurt: 4 articles (05/2013 - 09/2011)|
|8.||Cianfrocca, Roberta: 4 articles (10/2012 - 02/2009)|
|9.||Nicotra, Maria Rita: 4 articles (04/2011 - 07/2007)|
|10.||Liu, Glenn: 3 articles (02/2015 - 08/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Two reviewers searched and extracted data of the published trials and review articles on zibotentan for prostate cancer using the Medline, Embase and Cochrane Controlled Trials Register database. "
06/01/2013 - "Owing to the absence of demonstrable survival benefits in the ENTHUSE clinical studies, zibotentan is no longer under investigation as a potential treatment for prostate cancer."
11/15/2012 - "Patients were randomized 1:1 to zibotentan 10 mg/day or placebo, plus standard prostate cancer treatment. "
07/01/2010 - "Zibotentan for the treatment of castrate-resistant prostate cancer."
08/01/2008 - "As ET-1 may also mediate nociceptive effects and osteoblastic effects, there is much interest in clinically assessing ZD4054 in prostate cancer. "
07/01/2012 - "This study aimed to investigate the pharmacokinetic (PK) and safety profiles of the specific ET(A) receptor antagonist, zibotentan, in elderly, male Chinese patients with advanced solid tumors. "
02/01/2009 - "In vivo, ZD4054 led to a significant reduction in tumor growth in animals bearing ovarian tumor xenografts, and significantly inhibited tumor angiogenesis. "
06/01/2010 - "Accordingly, in HEY xenografts the coadministration of zibotentan with cisplatinum enhanced the efficacy of the cytotoxic drug alone in controlling tumor growth, associated with reduction in proliferation index and microvessel density. "
06/20/2005 - "As a result of this specificity, ZD4054 has the potential to block multiple ET(A)-induced pathological processes, while allowing beneficial ET(B)-mediated processes to continue, which may, in turn, lead to an effective cancer therapy."
06/01/2010 - "Remarkably, the combination of zibotentan with both cisplatinum and paclitaxel was very effective in inhibiting tumor growth, neovascularization, and cell proliferation, representing a preclinical endpoint to guide combination therapy in clinical trials."
|3.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2014 - "Efficacy of zibotentan in colorectal cancer--letter."
06/01/2014 - "Efficacy of zibotentan in colorectal cancer--response."
08/01/2013 - "With its known safety profile, we provide evidence for zibotentan's potential role as adjuvant therapy in colorectal cancer."
08/01/2013 - "Here, for the first time, we evaluate zibotentan, a specific ET(A) receptor antagonist, in the setting of colorectal cancer, in cellular models. "
08/01/2013 - "Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study."
|4.||Ovarian Neoplasms (Ovarian Cancer)
06/01/2010 - "We found that the combination of zibotentan with cisplatinum as well as zibotentan with paclitaxel was more effective at inhibiting ovarian cancer HEY cell proliferation induced by endogenous ET-1 than were the single agents alone. "
02/24/2009 - "ZD4054 treatment significantly inhibits metastases, suggesting that specific ET(A)R antagonists, by disabling multiple signaling activated by ET(A)R/beta-arrestin, may represent new therapeutic opportunities for ovarian cancer."
06/01/2010 - "Since clinical trial results have defined the combination of platinum and taxane as the standard of care in the management of ovarian cancer, here we explored the therapeutic efficacy of the integration of zibotentan with cytotoxic drugs having different modes of action. "
07/01/2007 - "In HEY ovarian cancer xenografts, ZD4054 significantly inhibited tumor growth to the same degree as paclitaxel. "
07/01/2013 - "Zibotentan (ZD4054) is an oral, specific ETA-receptor antagonist with demonstrated antitumour activity in xenograft models of human ovarian cancer. "
06/01/2006 - "In conclusion, our data demonstrate that ZD4054 is capable in inhibiting the proliferative activity of ET-1, indicating that this specific ET(A)R antagonist may be a potential candidate in developing novel treatment of ovarian carcinoma."
06/01/2006 - "The present study was designed to investigate the in vitro effects of trans, trans-2(4-methoxydhenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)-pyrrolidine-3-carboxylic acid (ZD4054), an orally active specific ET(A)R antagonist, on the ET-1-induced mitogenic effect in OVCA 433 and HEY ovarian carcinoma cell lines secreting ET-1 and expressing ET(A)R and ET(B)R mRNA. "
07/01/2007 - "Combined targeting of ET(A)R, by the specific ET(A)R antagonist ZD4054, and of EGFR by the EGFR inhibitor gefitinib (IRESSA), may offer improvements in ovarian carcinoma treatment. "
06/01/2006 - "ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation."
07/01/2007 - "The coadministration of ZD4054 enhanced the efficacy of gefitinib leading to partial (82%) or complete tumor regression on HEY ovarian carcinoma xenografts. "
|2.||Endothelin A Receptor
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)